이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A1-Free vs. Conventional Milk Metabolic Response Study

2026년 4월 28일 업데이트: Dennis A. Savaiano, Purdue University

A Randomized Crossover Study Evaluating Postprandial Glucose and Insulin Responses to A1-Free and Conventional Milk With and Without a Delayed Lactose Challenge in Healthy Adults

This study will examine how different types of milk affect blood sugar and insulin responses after eating. Specifically, the study compares milk that contains only A2 beta-casein protein (A1-free milk) to conventional milk, which contains both A1 and A2 proteins.

Participants will complete four study visits in which they will consume different milk-based beverages. These include lactose-containing milk and lactose-free milk followed by a lactose drink given later. Blood samples will be collected over several hours to measure glucose and insulin responses. Breath tests and questionnaires will also be used to assess digestion and gastrointestinal symptoms.

The goal of this study is to determine whether milk protein type influences metabolic responses and whether consuming lactose-free milk affects how the body processes lactose when it is consumed later.

연구 개요

상세 설명

Postprandial glucose and insulin responses are important indicators of metabolic health, even in individuals without diagnosed metabolic disease. The rate and pattern of nutrient digestion and absorption can influence these responses, and emerging evidence suggests that differences in milk protein composition, specifically the presence or absence of A1 beta-casein, may alter gastrointestinal function and metabolic outcomes.

This study is a randomized, double-blind, crossover trial designed to evaluate the effects of A1-free milk compared to conventional milk on postprandial metabolic responses in healthy adults. Participants will complete four experimental conditions in random order: (1) lactose-containing A1-free milk, (2) lactose-containing conventional milk, (3) lactose-free A1-free milk followed by a delayed lactose challenge, and (4) lactose-free conventional milk followed by a delayed lactose challenge.

The inclusion of both lactose-containing and lactose-free conditions allows for evaluation of two complementary questions. First, direct comparisons between lactose-containing A1-free and conventional milk will assess whether milk protein composition influences postprandial glucose and insulin responses under typical consumption conditions. Second, the lactose-free preload conditions, combined with a standardized delayed lactose challenge, are designed to evaluate whether prior milk consumption modifies subsequent metabolic responses to lactose exposure. This approach provides insight into potential differences in digestive kinetics, including gastric emptying, nutrient delivery, and lactose digestion and absorption.

During each study visit, participants will consume a standardized milk-based intervention following an overnight fast. In the lactose-free conditions, a lactose beverage matched to the amount of lactose typically present in the milk will be administered 60 minutes after milk consumption. Blood samples will be collected at multiple timepoints over a postprandial period to measure glucose and insulin concentrations and characterize response patterns, including early-phase responses and overall exposure.

Secondary and exploratory outcomes include breath hydrogen testing as a non-invasive marker of carbohydrate fermentation and lactose maldigestion, as well as gastrointestinal symptom assessments using validated questionnaires. These measures will be used to provide additional context for interpreting metabolic responses across conditions.

The crossover design allows each participant to serve as their own control, improving statistical power and reducing variability. The findings from this study will help clarify whether differences in milk protein composition influence metabolic responses and whether prior exposure to lactose-free milk alters the body's handling of lactose consumed at a later time.

연구 유형

중재적

등록 (추정된)

35

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

설명

Inclusion Criteria:

  • Ability/desire to provide informed consent
  • Are between 18 and 65 years of age
  • Are generally healthy, with no known metabolic or gastrointestinal conditions that would affect digestion or metabolism
  • Are willing to consume milk-based beverages and lactose-containing drinks as part of the study
  • Are willing to fast overnight (approximately 10-12 hours) prior to study visits and follow study instructions (e.g., diet and activity restrictions)
  • Are willing to attend all study visits and complete all study procedures (blood draws, breath tests, urine samples, questionnaires)
  • Are able to understand and provide written informed consent in English.

Exclusion Criteria:

  • You have a known allergy to milk or dairy products
  • You are currently pregnant, planning to become pregnant, or breastfeeding
  • You currently smoke or have used tobacco or nicotine-containing products within the past 3 months
  • You have a history of excessive alcohol use within the past 30 days
  • You have been diagnosed with diabetes (Type 1 or Type 2), prediabetes, or other metabolic conditions that affect glucose or insulin responses (such as insulin resistance, metabolic syndrome, or polycystic ovary syndrome [PCOS])
  • You have a history of gastrointestinal conditions that may affect digestion or absorption (such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, celiac disease, or severe irritable bowel syndrome)
  • You have had gastrointestinal surgery that alters normal digestive function (such as bariatric surgery or gastric bypass)
  • You have other medical conditions that may affect digestion or interfere with study results (such as Past or present: Organ transplant, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, Celiac disease, chronic constipation, diverticulosis, inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), small intestine bacterial overgrowth syndrome (SIBO), gastroparesis, gastro-esophageal reflux disease (GERD), Irritable Bowel Syndrome (IBS) or any other medical condition with symptoms that could confound collection of adverse events.)
  • You have used medications or supplements known to affect glucose metabolism, digestion, or gastrointestinal function within the following timeframes prior to enrollment:
  • Within 4 weeks: insulin, metformin, GLP-1 receptor agonists, corticosteroids, digestive enzymes, fiber supplements, and all oral or IV antibiotics
  • Within 2 weeks: bismuth-containing compounds (e.g., Pepto-Bismol) and proton pump inhibitors or acid suppressors (e.g., omeprazole [Prilosec], lansoprazole [Prevacid], esomeprazole [Nexium], pantoprazole [Protonix], rabeprazole [Aciphex])
  • Within 1 week: laxatives and stool softeners (e.g., Miralax, Colace, senna, lactulose, Citrucel, Metamucil, Fibercon), probiotics and prebiotics, gastrointestinal motility agents (e.g., Reglan, Linzess, Amitiza), and antidiarrheal medications (e.g., loperamide [Imodium], Lomotil)
  • You have had a recent infection within the past 30 days
  • You have been diagnosed with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C
  • You are currently undergoing chemotherapy
  • Height: ___ Weight: ___ BMI: ___ Weighing <16.5 kg or Body mass index > 35 kg/m2
  • You have participated in another clinical trial or used an investigational product within the past 30 days
  • You have any other condition that, as determined by the study team, would make participation unsafe or interfere with study results

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Lactose-Containing A1-Free Milk
Participants consume lactose-containing A1-free milk during one study visit. Blood, breath hydrogen, urine, and gastrointestinal symptom measures are collected over the 180 minute postprandial period.
A lactose-containing milk beverage containing A2 beta-casein and no A1 beta-casein, consumed during one experimental study visit.
다른 이름들:
  • A2 우유
  • A1-free milk
실험적: Lactose-Containing Conventional Milk
Participants consume lactose-containing conventional milk containing both A1 and A2 beta-casein during one study visit. Blood, breath hydrogen, urine, and gastrointestinal symptom measures are collected over the 180 minute postprandial period.
A lactose-containing conventional milk beverage containing both A1 and A2 beta-casein, consumed during one experimental study visit.
다른 이름들:
  • 기존 우유
  • A1/A2 milk
실험적: Lactose-Free A1-Free Milk With Delayed Lactose Drink
Participants consume lactose-free A1-free milk followed by a lactose drink administered 60 minutes after milk consumption. Blood, breath hydrogen, and gastrointestinal symptom measures are collected over the 180 minute postprandial period.
A lactose-free A1-free milk beverage consumed at the start of the study visit, followed by a lactose drink administered 60 minutes after milk consumption. The lactose drink is matched to the amount of lactose expected in the milk serving.
실험적: Lactose-Free Conventional Milk With Delayed Lactose Drink
Participants consume lactose-free conventional milk containing both A1 and A2 beta-casein followed by a lactose drink administered 60 minutes after milk consumption. Blood, breath hydrogen, and gastrointestinal symptom measures are collected over the 180 minute postprandial period.
A lactose-free conventional milk beverage containing both A1 and A2 beta-casein consumed at the start of the study visit, followed by a lactose drink administered 60 minutes after milk consumption. The lactose drink is matched to the amount of lactose expected in the milk serving.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Postprandial Plasma Insulin Incremental Area Under the Curve (iAUC)
기간: 0 to 180 minutes post-intervention during each study visit
Incremental area under the curve (iAUC) for plasma insulin concentrations following consumption of each study condition, measured from serial blood samples collected via an indwelling catheter.
0 to 180 minutes post-intervention during each study visit
Postprandial Plasma Glucose Incremental Area Under the Curve (iAUC)
기간: 0 to 180 minutes post-intervention during each study visit
Incremental area under the curve (iAUC) for plasma glucose concentrations following consumption of each study condition, measured from serial blood samples collected via an indwelling catheter.
0 to 180 minutes post-intervention during each study visit

2차 결과 측정

결과 측정
측정값 설명
기간
Early-Phase Postprandial Glucose and Insulin Response
기간: 0 to 60 minutes post-intervention
Early-phase postprandial response assessed by incremental area under the curve (iAUC) for plasma glucose and insulin concentrations.
0 to 60 minutes post-intervention
Time to Peak Plasma Glucose and Insulin Concentrations (Tmax)
기간: 0 to 180 minutes post-intervention
Time required to reach peak plasma glucose and insulin concentrations following each study condition.
0 to 180 minutes post-intervention
Circulating Metabolite Responses
기간: 0, 30, 60, and 120 minutes
Postprandial changes in circulating metabolites, including amino acids and acylcarnitines, measured from plasma samples to assess metabolic responses.
0, 30, 60, and 120 minutes
Breath Hydrogen Concentrations
기간: Baseline and every 30 minutes from 0 to 180 minutes post-intervention
Breath hydrogen levels measured as a non-invasive marker of carbohydrate fermentation and lactose maldigestion.
Baseline and every 30 minutes from 0 to 180 minutes post-intervention
Gastrointestinal Symptom Scores
기간: Baseline and at 60, 120, and 180 minutes post-intervention
Self-reported gastrointestinal symptoms (e.g., bloating, gas, abdominal discomfort) assessed using visual analog scale and Likert-type questionnaires.
Baseline and at 60, 120, and 180 minutes post-intervention
Urinary Galactose Concentrations
기간: Baseline and 180 minutes post intervention
Urinary galactose concentrations measured as an marker of lactose metabolism.
Baseline and 180 minutes post intervention

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Dennis A Savaiano, PhD, Purdue University

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 6월 15일

기본 완료 (추정된)

2026년 10월 31일

연구 완료 (추정된)

2027년 1월 31일

연구 등록 날짜

최초 제출

2026년 4월 28일

QC 기준을 충족하는 최초 제출

2026년 4월 28일

처음 게시됨 (실제)

2026년 5월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 5월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 4월 28일

마지막으로 확인됨

2026년 4월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다